Carcinoma, Neuroendocrine

• 

  Subject Areas on Research

  • A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. 
  • A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. 
  • ASO Author Reflection: Postoperative Chemotherapy for Nonmetastatic, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas. 
  • Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas. 
  • Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis. 
  • Aggressive variants of castration-resistant prostate cancer. 
  • Altered telomeres in tumors with ATRX and DAXX mutations. 
  • Alternative Splicing Provides a Novel Molecular Mechanism for Prostatic Small-cell Neuroendocrine Carcinoma. 
  • CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. 
  • Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). 
  • Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. 
  • Clonality of combined tumors. 
  • Cystic pancreatic neuroendocrine tumors: a clinicopathologic study. 
  • Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. 
  • Donor-Derived Neuroendocrine Carcinoma Transmission to Two Kidney Transplant Recipients Demonstrated by Short Tandem Repeat Analysis: A Case Report. 
  • Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. 
  • Evolving application of minimally invasive cancer operations at a tertiary cancer center. 
  • Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy. 
  • FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. 
  • Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway. 
  • High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not. 
  • Hyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis. 
  • Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma. 
  • Liver Mass: Thinking Out of the Box. 
  • MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. 
  • Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. 
  • N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. 
  • Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. 
  • Neuroendocrine carcinomas of the gallbladder: Lessons learnt from cases at opposite ends of the spectrum. 
  • Neuroendocrine differentiation of prostate cancer. 
  • Neuroendocrine lung tumors and disorders of the neuromuscular junction. 
  • Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. 
  • Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer. 
  • PC3 is a cell line characteristic of prostatic small cell carcinoma. 
  • Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms. 
  • Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. 
  • Primary Breast Neuroendocrine Tumor. 
  • Primary hepatic neoplasms arising in cirrhotic livers can have a variable spectrum of neuroendocrine differentiation. 
  • Primary high-grade neuroendocrine carcinoma emerging from an adenomatous polyp in the setting of familial adenomatous polyposis. 
  • Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. 
  • Primary tumor resection improves survival of gastrointestinal neuroendocrine carcinoma patients with nonresected liver metastases. 
  • Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. 
  • Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer. 
  • Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer. 
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. 
  • Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation. 
  • Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. 
  • Staging of esophageal cancer by EUS: staging accuracy revisited. 
  • Surgical management of medullary thyroid carcinoma. 
  • Survival outcomes in sinonasal carcinoma with neuroendocrine differentiation: A NCDB analysis. 
  • Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. 
  • TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. 
  • Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation. 
  • Targeting RET Kinase in Neuroendocrine Prostate Cancer. 
  • The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma. 
  • Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. 
  • Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. 
  • Use of Dexmedetomidine in a Parturient With Multiple Endocrine Neoplasia Type 2A Undergoing Adrenalectomy and Thyroidectomy: A Case Report. 
  • [Neuroendocrine differentiation in prostate cancer]. 
  • p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. 
• 

  Keywords of People

  • McLendon, Roger Edwin, Professor of Pathology, Pathology